Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature
| Autor: | Paola Codella, Matteo Ruggeri, Sabrina Prete, Silvia Coretti, Eugenio Di Brino, Federica Romano, Valentina Orlando |
|---|---|
| Přispěvatelé: | Coretti, Silvia, Romano, Federica, Orlando, Valentina, Codella, Paola, Prete, Sabrina, Di Brino, Eugenio, Ruggeri, Matteo |
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Cirrhosis Cost effectiveness Hepatitis C virus Prevalence cost-effectivene Review Bioinformatics medicine.disease_cause pharmacoeconomics medicine Intensive care medicine early detection cost-effectiveness Liver infection business.industry Health Policy screening Public Health Environmental and Occupational Health Hepatitis C medicine.disease Economic evaluation hepatitis C drug utilization Liver cancer business |
| Zdroj: | Risk Management and Healthcare Policy |
| ISSN: | 1179-1594 |
| Popis: | Background Hepatitis C is a liver infection caused by hepatitis C virus. Its main complications are cirrhosis and liver cancer. According to the World Health Organization (WHO), more than 185 million people worldwide are infected with hepatitis C virus and, of these, 350,000 die every year. Due to the high disease prevalence and the existence of effective (and expensive) medical treatments able to dramatically change the prognosis, early detection programs can potentially prevent the development of serious chronic conditions, improve health, and save resources. Objective To summarize the available evidence on the cost-effectiveness of screening programs for hepatitis C. Methods A literature search was performed on PubMed and Scopus search engines. Trip database was queried to identify reports produced by the major Health Technology Assessment (HTA) agencies. Three reviewers dealt with study selection and data extraction blindly. Results Ten papers eventually met the inclusion criteria. In studies focusing on asymptomatic cohorts of individuals at general risk the cost/quality adjusted life year of screening programs ranged between US $4,200 and $50,000/quality adjusted life year gained, while in those focusing on specific risk factors the incremental cost-effectiveness ratio ranged between $848 and $128,424/quality adjusted life year gained. Age of the target population and disease prevalence were the main cost-effectiveness drivers. Conclusion Our results suggest that, especially in the long run, screening programs represent a cost-effective strategy for the management of hepatitis C. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|